| 2015-05-04 |
102 |
|
for what ultimately issued as U.S.
Patent No. 7,276,250 patent entitled “Sustained release formulations…the
Orange Book patents because: (1) no patents exist on the brand drug; (2) the patents have
expired;…artificial act” of patent
infringement, permitting the patent owner to file a patent infringement suit…ER. This patent is expected to provide patent protection until
November 2023. The new patent will be listed…limitations on the types of patents that can be listed. Only
drug substance patents (active ingredient), drug |
External link to document |
| 2016-02-10 |
151 |
|
patent”), No. 5,662,933 (the “‘933 patent”), and
No. 7,276,250 …purchased the rights to four
patents — U.S. Patent No. 5,128,143 (the “143 patent”), No. 5,958,456
(the …of any unexpired patents listed in the
Orange Book; or (IV) that any unexpired patents listed in the Orange…artificial act” of patent infringement, permitting the brand company
to file a patent infringement suit…
‘143 patent in the Orange Book as covering Opana ER, and later added
the ‘456 and ‘933 patents. |
External link to document |
| 2016-02-25 |
162 |
|
“‘456
patent”), No. 5,662,933 (the “‘933 patent”), and No. 7,276,250
(the “‘250 patent”) (collectively… rights to four patents — U.S. Patent
No. 5,128,143 (the “‘143 patent”), No. …expiration of the
Penwest Patents, and Endo sued each for patent infringement.
RAC ¶¶ 84-109…enforceability of the ‘933 and ‘456
patents, as well as the ‘250 patent, which Endo had not even
accused…agreement to settle ongoing patent infringement
Case: 1:14-cv-10150 Document |
External link to document |
| 2016-03-02 |
164 |
|
for what ultimately issued as U.S.
Patent No. 7,276,250 patent entitled “Sustained release formulations…the
Orange Book patents because: (1) no patents exist on the brand drug; (2) the patents have
expired;…artificial act” of patent
infringement, permitting the patent owner to file a patent infringement suit…ER. This patent is expected to provide patent protection until
November 2023. The new patent will be listed…limitations on the types of patents that can be listed. Only
drug substance patents (active ingredient), drug |
External link to document |
| 2020-04-29 |
562 |
|
Exclusive License USA
6,022,539 June 3, 2019 …issued patents, 36 U.S. patent
applications pending, 157 foreign issued patents and 72 foreign patent applications… by patent rights or have limited patent life and will soon lose patent protection. Loss of patent
protection…five patents relating to VASOSTRICT® by the U.S. Patent and Trademark Office (PTO). These patents expire…243 U.S. issued patents, 64 U.S. patent applications pending, 551 foreign issued patents, and 150
foreign |
External link to document |
| 2020-04-29 |
581 |
|
Exclusive License USA
6,022,539 June 3, 2019 …issued patents, 36 U.S. patent
applications pending, 157 foreign issued patents and 72 foreign patent applications… by patent rights or have limited patent life and will soon lose patent protection. Loss of patent
protection…five patents relating to VASOSTRICT® by the U.S. Patent and Trademark Office (PTO). These patents expire…243 U.S. issued patents, 64 U.S. patent applications pending, 551 foreign issued patents, and 150
foreign |
External link to document |
| 2020-08-18 |
693 |
|
additional patents that it claimed covered Opana ER, including U.S. Patent No. 8,309,122 (the
“’122 patent…Endo’s
patents: U.S. Patent Nos. 6,958,456 (the “’456 patent”) and 5,662,933 (the “’933 patent”) (the
… patent”); U.S. Patent No. 8,329,216 (the “’216 patent”); and U.S. Patent No. 8,871,779 (the
“’779 patent…Original Opana ER infringed the ‘122
patent, the ‘216 patent, and U.S. Patent No. 8,808,737.118 This lawsuit…opinion of Plaintiffs’ patent expert, Glen Belvis,
who opined that a reasonable patent attorney would have |
External link to document |
